Form 4: BioXcel Exec Converts RSUs to Common Stock

BioXcel Therapeutics' Chief Legal Officer, Javier Rodriguez, converted restricted stock units into common stock on September 14 and 15, 2025.

Summary

• Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary of BioXcel Therapeutics, Inc. (BTAI), reported transactions involving the conversion of Restricted Stock Units (RSUs) into common stock.
• On September 14, 2025, 33 RSUs were converted into 33 shares of common stock. Following this transaction, Rodriguez beneficially owned 6,692 shares of common stock directly.
• On September 15, 2025, an additional 35 RSUs were converted into 35 shares of common stock. After this transaction, Rodriguez's direct beneficial ownership increased to 6,727 shares of common stock.
• These conversions were related to RSU grants from March 14, 2022 (521 RSUs) and March 15, 2023 (562 RSUs), which vest over time subject to continuous employment.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions involving the conversion of Restricted Stock Units (RSUs) into common stock, which is a standard part of executive compensation. This action increases the executive's direct ownership in the company, which can be viewed as a neutral to slightly positive signal of alignment with shareholder interests, but does not indicate significant new operational or financial developments.

Positives

• Increased direct beneficial ownership of common stock by a key executive, Javier Rodriguez, by a total of 68 shares (33 + 35) through RSU conversions.
• The transactions represent the vesting and conversion of previously granted equity compensation, aligning executive incentives with shareholder interests.

Future Outlook

Not applicable to this filing type, which reports past insider transactions.

Industry Context

This filing reports a routine insider transaction related to executive compensation, which is a common practice across publicly traded companies in all industries, including biotechnology. It does not provide specific insights into broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The transactions result in a slight increase in direct insider ownership, potentially signaling continued executive confidence in the company's future.

Next Steps

• Continued vesting of remaining Restricted Stock Units (RSUs) granted on March 14, 2022, and March 15, 2023, subject to Javier Rodriguez's continuous employment with BioXcel Therapeutics, Inc.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation (RSU conversions). While it shows an executive increasing their direct ownership, these are not open market purchases and do not provide sufficient new information regarding the company's operational performance, financial health, or strategic direction to warrant a change from a 'hold' recommendation based solely on this filing.

Keywords

BioXcel Therapeutics, BTAI, Form 4, Insider Transaction, Restricted Stock Units, RSU Conversion, Executive Compensation, Javier Rodriguez, Common Stock